XML 29 R19.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Information [Abstract]  
SEGMENT INFORMATION

NOTE 13. SEGMENT INFORMATION

 

The Company has determined it operates as a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company’s chief operating decision maker, its Chief Executive Officer (the “CEO”), manages the Company’s operations on a consolidated basis. The CEO assesses the segment’s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment’s personnel and general and overhead costs.

  

In addition to the significant expense categories included within net loss presented in the Company’s condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses (in thousands):

 

    Three Months Ended
March 31,		  
    2026     2025  
Personnel-related costs   $ 4,038     $ 8,431  
General and overhead costs     3,291       3,611  
                 
Program costs                
Briquilimab platform     266       1,957  
CMO     882       2,138  
CSU     2,378       2,746  
Asthma     (327 )     1,393  
CIndU     424       885  
SCID     —       523  
MDS/AML     —       118  
Total program costs     3,623       9,760  
Total operating expense     10,952       21,802  
Other income, net     9,778       561  
Net loss   $ (1,174 )   $ (21,241 )

 

All long-lived assets are located in the United States.